



IMPACT

YEAR IN REVIEW

2020

MRIGlobal

The science you expect.
The people you know.



CONTENTS

3	LETTER FROM THE CEO
4	CONFRONTING COVID
8	DEFENSE
11	HEALTH
13	SUSTAINABLE WORLD
15	NREL
16	FINANCES AND LEADERSHIP



2020 CHALLENGES & CHANGES

FROM THE CEO

This was a year of unprecedented challenges and remarkable opportunity for MRIGlobal. We were challenged by the COVID-19 pandemic.

Our colleagues met the challenges while working from home, meeting virtually, and staying connected with our customers with the same care, trust, and technical expertise that mark MRIGlobal's brand. As the COVID-19 pandemic continues to dominate our world, MRIGlobal's deep experience in predicting, preventing and controlling infectious diseases like Ebola, MERS, and now COVID-19 impacts the outbreak in myriad ways.

The timely opening of our expanded Diagnostics Center of Excellence in late 2019 equipped us to enlarge our research and development portfolio and take on exciting new partners like the Defense Advanced Research Projects Agency and the Bill & Melinda Gates Foundation.

We are developing chemistry and devices for the Department of Defense's next generation of clinical diagnostics and developing virtual training modules for COVID-19-related work for Africa's national public health network.

Within MRIGlobal, a major strategic initiative to restructure and streamline our operations culminated with the launch of our new organizational model in October. The transition positions us to efficiently and seamlessly provide diverse opportunities for our staff, better serve our customers, and grow our mission impact.

Racial inequities moved to the forefront and challenged our communities and nation in unprecedented ways this year. At MRIGlobal, we're dedicated to fostering an open-minded, collaborative workplace that respects and celebrates our diverse colleagues, and we'll continue our efforts to support growth of a diverse STEM workforce.

Indeed, it was an unprecedented and remarkable year, highlighted by the dedication and effort of the MRIGlobal team. I'm proud of what we accomplished this past year and am looking forward to an equally remarkable new year.

Thomas M. Sack, Ph.D.

President and Chief Executive Officer

CONFRONTING COVID

In the face of the global SARS-CoV-2 (COVID-19) pandemic, MRIGlobal's expertise in predicting, preventing, and controlling infectious outbreaks such as Ebola, SARS and MERS dominated our work this year.

Our research experts are making diverse and significant contributions in combating COVID-19.



IN THE LAB

We dedicated MRIGlobal's state-of-the-art Diagnostics Center of Excellence in late 2019.

That timely launch equipped us to address a surge of new commercial and government projects focused on the development and testing of COVID-19 diagnostics.

This work moved several diagnostic devices through Food and Drug Administration Emergency Use Authorization. MRIGlobal's COVID-19 diagnostic portfolio continues to grow as diagnostic companies push towards FDA clearance.



01

Early in the outbreak, MRIGlobal focused on the development of Emergency Use Authorization (EUA) assays for SARS-CoV-2 corona virus/COVID-19, followed by further testing to obtain Food and Drug Administration (FDA) clearance for the diagnostic assays. MRIGlobal also evaluated the efficacy and safety of vaccines and therapeutics, including efforts to discover new antiviral candidates. Our research teams are ramping up to support human clinical trials of medical countermeasures now under development.



02

MRIGlobal developed a hamster model to test the efficacy of therapeutics, prophylaxis, and vaccines designed specifically against SARS-CoV-2. Researchers performed an extensive Natural History Study to understand the disease progression and where to best target drugs against the disease.

03

MRIGlobal tested the effectiveness of several disinfectants and devices aimed specifically at decontamination of SARS-CoV-2. Testing included UV, ozone, hydrogen peroxide, and plasma technologies. Several of these technologies have proven 99.99% effective at reducing infection.

04

MRIGlobal verified the effectiveness of drug candidates in in vitro tissue culture assays against SARS-CoV-2. Several drugs have progressed to the FDA for clearance for the potential treatment of COVID-19. Others are under consideration for evaluation using MRIGlobal's hamster efficacy model.

BIOSAFETY AND SECURITY

In offices, businesses, and schools

Returning to the workplace, campuses, and businesses amid a pandemic calls for credentialed biosafety experts to assess programs and for risk and biosafety. MRIGlobal has provided critical guidance to businesses, schools, and laboratories to prepare their facilities and their inhabitants for a safe return to normal. Our experts helped these organizations understand the public health variables in their communities and to change their normal operations as the situation evolves. MRIGlobal's professionals are providing relevant, up-to-date site assessments and training in the U.S. and internationally.



IN THE FIELD

Evacuation, diagnostics, and treatment

Over the past two decades, MRIGlobal mobile lab solutions have become essential infrastructure, bringing gold-standard lab capability to the field to diagnose infectious disease and other biological and chemical threats around the world.

This year, new and updated versions of mobile labs to address a myriad of threats have been in high demand as clients like the Department of Defense seek to expand their flexibility to meet the growing need for COVID-19 testing.



01

Design work was already underway on Athena, MRIGlobal's newest mobile lab, when the global COVID-19 outbreak hit. An expandable mobile laboratory space on par with brick and mortar labs, Athena offers 82% more floor space and 40% more lab bench space than prior models, without adding to the shipping footprint or cost. As with earlier mobile lab models, Athena is rapidly deployable to remote, austere environments worldwide. Units are shipped by air, boat or truck, just like any ISO standard 20-foot-long shipping container.



02

Designed and fabricated to address the Ebola outbreak in 2014, CBCS played a vital role this year transporting COVID-19 infected patients to life-saving medical care in a safe, completely bio-contained unit. The state-of-the-art CBCS is 8 feet tall, 8 feet wide, 44-feet long, weighs 22,000 pounds, and is designed to fit neatly inside cargo planes. The unit contains basic medical equipment and oxygen to provide comfort to patients for up to 16 hours while supporting strict biosafety best practices.



03

Mercury Lab is a single-person, portable lab workbench in a lock-and-go case designed for point-of-need operations. Mercury Lab provides logistical streamlining so that samples for advance molecular diagnostics, biosurveillance and forensic testing can be processed on site. This safeguards the quality of the sample by eliminating the need for extended transport and ultimately reduces the time to acquire an actionable result.

COVID-19 COMMUNITY ENGAGEMENT

MRIGlobal researchers, from virologists to biosafety professionals, shared insights about the global COVID-19 pandemic and other timely topics.

Many staff have served as subject matter experts on community town hall panels and on popular question-and-answer expert platforms like Quora and Reddit Ask Me Anything sessions, NPR, and numerous local, national, and international media outlets.



Harnessing the power of artificial intelligence (AI) to guide treatment decisions

In the fight against COVID-19, time is of the essence to come up with the most effective treatment options. MRIGlobal Science Advisor Gene Olinger, Ph.D., was part of a multidisciplinary research team that developed a pioneering artificial intelligence (AI) tool to dramatically increase the efficiency of infectious disease treatment development.

Typically, when new, deadly bacterial or viral infections emerge, researchers develop a treatment that combines several different drugs – a labor intensive, time consuming, trial-and-error process to identify drug candidates and appropriate dosages.

The platform is known as 'IDentif.AI' (Identifying Infectious Disease Combination Therapy with Artificial Intelligence). Research was led by Professor Dean Ho from the National University of Singapore.

The team used 12 carefully selected drug candidates for treating infection in lung cells, then applied AI to significantly reduce the number of experiments needed to interrogate the range of combinations and optimal dosages of the 12 drugs. Using this process, it took the team three days to come up with multiple drug regimens out of billions of combinations, an unprecedented level of speed and accuracy.



Interactive Task Guidance
with Augmented Reality



AR Instructions

IMPACT

Pioneering AI tools could dramatically increase the efficiency of infectious disease treatment development and prepare us for pandemics like COVID-19.

Grant to establish virtual training for lab and data analytics awarded by the Bill & Melinda Gates Foundation

MRIGlobal received a \$250,000 grant to increase expertise for diagnostics, epidemiology, and COVID-19 disease surveillance on the African continent from the Bill & Melinda Gates Foundation. It is the first time MRIGlobal has received a grant from the Foundation.

MRIGlobal will establish virtual training modules for laboratory and data analytics work related to

COVID-19 epidemiology for use by labs partnered with Africa's national public health network.

An important outcome of the program will be achieved when each laboratory has customized procedures in place and highly trained staff to add the COVID-19 sequencing assay to their laboratory testing capability.

The team will conduct the remote training to laboratory staff by leveraging existing online communities of practice, live streaming sessions, and other routes to learning as appropriate to the needs and resources of each partner laboratory.



IMPACT

Labs trained and equipped to test for COVID-19 will have improved ability to address the spread of the disease on the African continent.

DEFENSE

01

Cutting-edge simulators prepare warfighters for real-world scenarios

For years, the military has relied on Nuclear Biological Chemical Reconnaissance Vehicles (NBCRV) to visualize and navigate battlefield threats like dangerous chemical, biological, radiological, or nuclear weapons at close range. Unmanned ground vehicles can be remotely operated to conduct sampling, provide valuable situational awareness for the soldier, and increase combat power.

While traditional training methods (like lectures and demonstrations) on these sophisticated, multi-million dollar vehicles are tried and true, simulator-based instruction can accelerate and enhance comprehension. Trainees receive hands-on experience with equipment and environments before they ever touch real-world machines.

For the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), MRIGlobal software engineers are developing an acclaimed sensor suite upgrade that integrates CBRN sensors onto reconnaissance vehicles.

Building on that expertise, MRIGlobal, in partnership with ForgeFX Simulations, is designing a cutting-edge modern simulator for training use on a full suite of manned and unmanned ground vehicles and the sensors they contain.

With a mouse, gamepad controller, and video technology, the soldier can learn to drive and operate the reconnaissance vehicle in a variety of simulated scenarios. Training involves state-of-the-art game development tools and techniques.



IMPACT

Advanced training tools designed by MRIGlobal better prepare warfighters for real-world scenarios when navigating battlefield threats.



02

Leading breakthrough technology for the Department of Defense (DOD)

MRIGlobal’s expertise in global health surveillance has been tapped by the Defense Advanced Research Projects Agency (DARPA) in its mission to fund and commission breakthrough technologies for the Department of Defense.

For the Detect It with Gene Editing Technologies (DIGET) program, MRIGlobal leads an elite team of research partners (Mammoth Biosciences, Draper, IDbyDNA, University of California San Francisco) to develop chemistry and devices for the DOD’s next generation of clinical diagnostics.

The DIGET program will provide comprehensive, specific, trusted information about health threats to medical decision-makers within minutes – even in remote regions of the globe.

DIGET’s vision incorporates two devices. One is a handheld, disposable point-of-need device that screens samples for at least 10 pathogens or host biomarkers at once. That device pairs with a massively multiplexed detection platform capable of screening clinical and environmental samples for more than 1,000 targets simultaneously.

03

Advanced testing system offers near real-world environment

When it comes to protecting soldiers from chemical warfare threats, the military relies on technologies that provide reliable advance notice of impending danger.

Passive infrared detection systems are a leading early threat notification option and are under investigation for use in a variety of deployment modalities, including the Nuclear Biological Chemical Reconnaissance vehicle. However, safe and realistic testing of passive infrared devices has proved to be challenging for the defense community.

IMPACT

MRIGlobal’s leadership in developing elite, breakthrough technologies helps inform medical decision-makers with timely, accurate data. This helps to prevent the spread of disease, enable timely deployment of countermeasures, and improve the standards of care after diagnosis.

DEFENSE

04

For JPEO-CBRND MRIGlobal engineers addressed the problem by developing a novel test platform that offers the ability to safely and controllably challenge a passive infrared detection system in a real-world scenario than has previously been accomplished.

Engineers successfully solved several notable challenges. These include: safely containing the chemical vapor used in the test, ensuring the test system temperature matches that of the ambient environment, and making the system easily relocatable to allow different environments to be considered, all the while providing the ability to fully operate the test system remotely. Use of this test system is expected to begin in the coming months and will allow for maturation of remote chemical vapor detection systems in realistic environments.



05

Safeguarding our postal system workers

Protecting U.S. Postal Systems (USPS) workers from biological threats is the objective of MRIGlobal's collaboration with Northrup Grumman and Cepheid.

MRIGlobal is testing and evaluating the analytical sensitivity and specificity of Cepheid's new GeneXpert assay for the Postal Systems Biohazard Detection System. Intended for use with environmental samples in USPS facilities, the new assay is a rapid, automated, and qualitative test for real-time detection of Anthrax.

IMPACT

This next generation of tests will update and improve on current reagents, enabling the USPS to more effectively protect its employees and customers from biological threats.

HEALTH



01

Eliminating the threat to global pork production

African Swine Fever Virus (ASFV), a highly contagious and deadly disease, has no vaccine or effective treatment. ASFV threatens global pork production and is rapidly spreading in China, Asia, and Europe.

While most vaccines have been designed to elicit antibody responses, research indicates that a sustained targeted T-cell response is required for protection against ASFV.

Senior Scientist Luca Popescu, Ph.D., DVM, and his team that includes MBF Therapeutics, is focused on applying immunotherapeutic advances to solve the challenging infectious disease threat of ASFV. The development strategy focuses on creating DNA-based vaccines that elicit potent T-cell responses to a multiplicity of conserved antigens to achieve broad-spectrum protection.

IMPACT

An effective, broad-spectrum ASFV vaccine could greatly reduce the devastating impact of African Swine Fever Virus to the global swine industry and food supply.

02

MRIGlobal partners with American Society for Microbiology

Program builds on MRIGlobal infection protection and control expertise in post-Ebola crisis Liberia

The 2014-2016 Ebola outbreak in West Africa – and now the COVID-19 global outbreak – are significantly impacting Liberia’s national health network. As a result, Liberia strives to significantly improve its ability to control infectious disease outbreaks. With the American Society for Microbiology and Linda S. Barnes Consulting, MRIGlobal is integrating quality-assured laboratory diagnostic testing, infection prevention and control, and blood transfusion practices to amplify Liberia’s health services network.

With three strategic areas – laboratory strengthening, infection prevention and control, and increased access to safe blood transfusion services – the project aims to reduce the burden of disease from public health threats across Liberia.

Goals include facilitating the transition of Liberia’s National Public Health Reference Laboratory – which MRIGlobal helped to build – to its new site.

The program also focuses on implementing site-specific national infection protection and control protocols, and providing training and tools for the National Blood Services and Transfusion Program.

HEALTH

Large scale manufacturers rely on MRIGlobal to bridge the gap between drug discovery and commercialization.

Our expertise in accelerating products from concept through the highly regulated and complex investigational new drug application process ensures products are safe for patients based on rigorous method evaluation and stability testing. As problem solvers, we bring unique solutions to pharma from drug discovery to manufacturing.

04

Propelling new treatments for inflammatory disease and multiple sclerosis

MRIGlobal partnered with a biotechnology client to propel FDA approval of its new therapeutic drug option for the treatment of adults with relapsing multiple sclerosis.

MRIGlobal applied its analytical chemistry expertise in monitoring the manufacturing process and custom synthesis of drug candidates for future use and testing. We also provided analytical reports on drug related compounds to support ongoing clinical trials, and provided certificates of analysis in compliance with regulatory agencies to support our client's FDA submission.

Another MRIGlobal development-stage biotechnology client made significant progress toward achieving FDA approval for a medication on track to improve the treatment of inflammatory diseases treated by dermatologists. MRIGlobal provides repository storage and analytical characterization of drug ingredients in clinical studies evaluating the safety, tolerability and efficacy of the dermatology therapeutic in moderate to severe acne patients. The medication, a once-weekly topical application, offers opportunity for greater patient treatment compliance and success.



IMPACT

MRIGlobal's expertise in drug discovery and commercialization propels new treatments for multiple sclerosis and acne to improve quality of life and contribute to improved treatment outcomes.

SUSTAINABLE WORLD

Our engineering expertise focuses on emerging energy technologies and systems, and enhancements of transportation safety. Developing and transitioning scientific and engineering advances in the energy and transportation sectors have been hallmarks of MRIGlobal programs for more than 75 years.



01

Safe, reliable power in remote areas of the world

Health care facilities require reliable power sources. In remote areas where generators provide the main source of energy, fuel can be in short supply, making reliable power difficult to obtain.

As a result, hospitals and labs are sometimes forced to shut down to conserve fuel, putting clinical care and research operations at risk.

Partnered with the University of North Carolina, MRIGlobal engineers delivered a reliable and resilient solution to their Lassa Fever Laboratory located on the Phebe Hospital compound near Gbarnga, Liberia. Relying on decades of experience, MRIGlobal field engineers led design and installation of power solutions to ensure safe, accessible energy sources for Liberia's far-flung health care operations.

IMPACT

Safe, reliable energy sources help maintain access to health care in remote areas around the globe.

02

On a mission to improve energy access in sub-Saharan Africa

The United Nations estimates there are approximately 1.1 billion people around the world without any access to electricity and more than 650 million of them live in sub-Saharan Africa.

Extending national grid infrastructure to remote rural areas is both expensive and time consuming. Decentralized minigrids based on renewable energy like wind and solar energy offer a viable and quick solution for rural populations in need of access to energy.

MRIGlobal's Sayan Chakraborti leads a United States Trade Development Association-funded feasibility study for rural electrification in the Lake Volta region of Ghana. The study will assess electricity demands and impacts, design solar and battery powered minigrids, configure distribution networks and prepare a project implementation plan to help the Ghana Ministry of Energy reach its universal energy access goals.

IMPACT

Completion of the project will fill a critical need for rural electrification in Ghana and ultimately transform and improve lives.

SUSTAINABLE WORLD



03

Making smarter decisions with traffic planning tool

Roadway treatments intended to improve the safety of motor-vehicle drivers can sometimes have an adverse effect on the safety of pedestrians and bicyclists.

A decision tool and user guide developed by MRIGlobal's traffic engineers is helping planners, designers, and safety engineers identify tradeoffs in safety and mobility between motorists, pedestrians, and bicyclists. The tool provides state and local highway agencies with a better understanding of the impact of most types of roadway and intersection safety treatments, giving them alternative strategy options during safety countermeasure selection.

IMPACT

At-risk bicyclists and pedestrians are safer as a result of an improved roadway design decision-making process designed by MRIGlobal.



04

SolarTAC, GridNXT demand ramps up

Demand for renewable energy technologies is booming. As a result, MRIGlobal's Solar Technology Acceleration Center (SolarTAC) and microgrid test and demonstration facility GridNXT are increasingly sought after to develop, test at scale and make products commercially ready in a fast, cost effective manner. The 78-acre site provides an exciting venue for commercial and federal partners to test, validate and demonstrate full-scale technologies under full environmental conditions. In 2021, MRIGlobal is on track to have 11 companies operating at the site.



05

Strategic partnership projects at NREL

MRIGlobal has been the management and operating partner for the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL) since 1977.

Partnerships have been, and continue to be, key to the National Renewable Energy Laboratory’s (NREL) success and central to its mission.

Public-private partnerships are gaining momentum. NREL has nearly 900 active partnership agreements with almost 600 unique partners in industry, government, and academia. These associations accelerate fresh ideas, new ways of thinking, and novel research in the energy space.

“As global energy use continues to increase, we must ensure our energy sources are safe, secure, and reliable. This is the important work that dedicated NREL researchers, scientists, and professionals strive to move forward each day,” said Dr. Martin Keller, NREL Director.

“Our work would not be possible without the support of the U.S. Department of Energy and the many other global, national, and local partners and stakeholders who are also vested in solving worldwide energy challenges.”

IMPACT

These collective efforts have produced incredible results, empowering innovation at every level, advancing economic growth, and fueling American energy leadership with and economic impact of \$1.4 billion nationwide.

06

NREL’s newest supercomputer and award-winning energy systems integration facility continue to impress

Scientific computing is increasingly critical to renewable energy and energy efficiency research.

For years, NREL leaned on the power of its Peregrine supercomputer to advance projects with heavy computing requirements, but last year the laboratory welcomed its successor—Eagle—which has more than tripled the laboratory’s computing capability.

Like Peregrine, Eagle is warm-water liquid cooled, which means 97% of waste-heat is captured and available for reuse in office and lab spaces. Eagle was designed for efficiency and the data center, where Eagle built its nest, has received numerous awards for efficiency.


NREL is one of the few to win the prestigious Data Center Dynamics Data Center Eco-Sustainability Award, bolstering the laboratory’s status as a world leader in data center efficiency and sustainability.

IMPACT


Advanced, more efficient computing capabilities translate to energy savings as well.

FINANCIALS & LEADERSHIP

REVENUE (\$M)



2020 NET INCOME (\$M)



CHAIRMAN

David F. Oliver
Attorney
BerkowitzOliver LLP



VICE CHAIRMAN

David B. Dillon
Retired Chairman of
the Board & Chief
Executive Officer
The Kroger Company

BOARD MEMBERS

Dan. E. Arvizu, Ph.D.
Chancellor
New Mexico State University

Pamela R. Berneking
Retired Chief Commercial Officer
Community America Credit Union

Alexander G. Garza, M.D., M.P.H.
Chief Medical Officer
SSM Health

Douglas A. Girod, M.D.
Chancellor
University of Kansas

David E. Hall
Executive Vice Chairman
Hallmark Cards, Inc.

Amy Nachtigal
Chief Financial Officer
Saint Luke's Health System's (SLHS)

Thomas M. Sack, Ph.D.
President and CEO
MRIGlobal

Neal Sharma
Co-founder and CEO
DEG

Scott M. Smith, P.E.
Retired Chief Executive Officer
The HNTB Companies

Julia M. Wilson
Retired Executive VP/CPO
Cerner Corporation



EXECUTIVE TEAM (From L to R)

Robert Conklin,
Vice President,
Research Operation

Martin Nevshemel,
Vice President, Chief
Financial Officer and
Treasurer

Thomas Sack,
President and Chief
Executive Officer

Rachel Beichley,
Vice President,
General Counsel and
Corporate Secretary

Dean Gray,
Vice President,
Defense

LIFE TRUSTEE MEMBERS

Charles W. Battey
Tom Bowser
Barrett Brady

Richard C. Green Jr.
William A. Hall
Irvine O. Hockaday Jr.

A. Drue Jennings J.D.
Robert A. Kipp
John C. McKelvey

Louis W. Smith
James L. Spigarelli Ph.D.

BOARD OF TRUSTEES

C. Mauli Agrawal Ph.D.
Malcolm M. Aslin
Barbara F. Atkinson M.D.
Alan L. Atterbury
Guy H. Bailey Ph.D.
Kevin G. Barth
W. H. Bates J.D.
Jonathan E. Baum
William S. Berkley
Thomas M. Bloch
Daniel P. Bolen J.D., LL.M.
Michael Braude
Arthur D. Brookfield II
Phillip J. Brown
J. Grant Burcham
Wayne O. Carter D.V.M.,
Ph.D., D.A.C.V.I.M.
Michael J. Chesser
Mun Choi Ph.D.
Cecil W. Cupp III
Thomas B. Curran S.J.

Brady J. Deaton Ph.D.
Peter James deSilva
Terrence P. Dunn
John M. Edgar J.D.
Steven L. Edwards
Debra Ellies Ph.D.
Melinda Estes M.D., M.B.A.
David W. Frantze J.D.
Esther L. George
Kent Glasscock
Stephen E. Gound
Greg M. Graves P.E.
Robert K. Green J.D.
George Guastello
Wendy Guillies
John E. Haaland Ph.D.
Marc B. Hahn DO
Donald J. Hall
Donald J. Hall Jr.
G. Richard Hastings
James A. Heeter

Doranne M. Hudson
Edward Randolph Jayne II
Roy Jensen M.D.
Mark R. Jorgenson
Gordon E. Lansford III
Peter S. Levi
Fred J. Logan Jr.
Fred W. Lyons Jr.
Mary V. McClure
Patrick J. McCown
Laura McKnight
Maria E. Meyers
Michael F. Morrissey
Leo E. Morton
Richard B. Myers
Don Nissanka
Randall L. O'Donnell Ph.D.
Thomas D. O'Grady P.E.
Timothy T. Petty
Joseph Reardon J.D.
Robert D. Regnier

Robert J. Reintjes Sr.
Dennis Ridenour
Madeline Romious
Kristy A. Schloss
Jewel D. Scott
James C. Shay
Charles W. Shields
Robert D. Simari M.D.
Dolph C. Simons Jr.
Ronald Slepitzka Ph.D.
Jimmie T. Stark CPA
Robert J. Swain
Jefferson W. Tester Ph.D.
Mark C. Thompson J.D.
Vincent Wagner
David A. Warm
Maurice Watson
Scott Weir Ph.D., PharmD
Deborah L. Wilkerson
Walter H. Wulf Jr.



**The science you expect.
The people you know.**

www.mriglobal.org
816-753-7600

FOLLOW US

